瀏覽器不支援
chrome 使用chrome瀏覽器,輕鬆學英文。

如有任何問題,歡迎聯絡我們

下載App 希平方
攻其不背
App 開放下載中
下載App 希平方
攻其不背
App 開放下載中
免費註冊
! 這組帳號已經註冊過了
Email 帳號
密碼請填入 6 位數以上密碼
已經有帳號了?
忘記密碼
! 這組帳號已經註冊過了
您的 Email
請輸入您註冊時填寫的 Email,
我們將會寄送設定新密碼的連結給您。
寄信了!請到信箱打開密碼連結信
密碼信已寄至
沒有收到信嗎? 點這裡重寄一次
如果您尚未收到信,請前往垃圾郵件查看,謝謝!

恭喜您註冊成功!

查看會員功能

註冊未完成

《HOPE English 希平方》服務條款關於個人資料收集與使用之規定

隱私權政策
上次更新日期:2014-12-30

希平方 為一英文學習平台,我們每天固定上傳優質且豐富的影片內容,讓您不但能以有趣的方式學習英文,還能增加內涵,豐富知識。我們非常注重您的隱私,以下說明為當您使用我們平台時,我們如何收集、使用、揭露、轉移及儲存你的資料。請您花一些時間熟讀我們的隱私權做法,我們歡迎您的任何疑問或意見,提供我們將產品、服務、內容、廣告做得更好。

本政策涵蓋的內容包括:希平方 如何處理蒐集或收到的個人資料。
本隱私權保護政策只適用於: 希平方 平台,不適用於非 希平方 平台所有或控制的公司,也不適用於非 希平方 僱用或管理之人。

個人資料的收集與使用
當您註冊 希平方 平台時,我們會詢問您姓名、電子郵件、出生日期、職位、行業及個人興趣等資料。在您註冊完 希平方 帳號並登入我們的服務後,我們就能辨認您的身分,讓您使用更完整的服務,或參加相關宣傳、優惠及贈獎活動。希平方 也可能從商業夥伴或其他公司處取得您的個人資料,並將這些資料與 希平方 所擁有的您的個人資料相結合。

我們所收集的個人資料, 將用於通知您有關 希平方 最新產品公告、軟體更新,以及即將發生的事件,也可用以協助改進我們的服務。

我們也可能使用個人資料為內部用途。例如:稽核、資料分析、研究等,以改進 希平方公司 產品、服務及客戶溝通。

瀏覽資料的收集與使用
希平方 自動接收並記錄您電腦和瀏覽器上的資料,包括 IP 位址、希平方 cookie 中的資料、軟體和硬體屬性以及您瀏覽的網頁紀錄。

隱私權政策修訂
我們會不定時修正與變更《隱私權政策》,不會在未經您明確同意的情況下,縮減本《隱私權政策》賦予您的權利。隱私權政策變更時一律會在本頁發佈;如果屬於重大變更,我們會提供更明顯的通知 (包括某些服務會以電子郵件通知隱私權政策的變更)。我們還會將本《隱私權政策》的舊版加以封存,方便您回顧。

服務條款
歡迎您加入看 ”希平方”
上次更新日期:2013-09-09

歡迎您加入看 ”希平方”
感謝您使用我們的產品和服務(以下簡稱「本服務」),本服務是由 希平方 所提供。
本服務條款訂立的目的,是為了保護會員以及所有使用者(以下稱會員)的權益,並構成會員與本服務提供者之間的契約,在使用者完成註冊手續前,應詳細閱讀本服務條款之全部條文,一旦您按下「註冊」按鈕,即表示您已知悉、並完全同意本服務條款的所有約定。如您是法律上之無行為能力人或限制行為能力人(如未滿二十歲之未成年人),則您在加入會員前,請將本服務條款交由您的法定代理人(如父母、輔助人或監護人)閱讀,並得到其同意,您才可註冊及使用 希平方 所提供之會員服務。當您開始使用 希平方 所提供之會員服務時,則表示您的法定代理人(如父母、輔助人或監護人)已經閱讀、了解並同意本服務條款。 我們可能會修改本條款或適用於本服務之任何額外條款,以(例如)反映法律之變更或本服務之變動。您應定期查閱本條款內容。這些條款如有修訂,我們會在本網頁發佈通知。變更不會回溯適用,並將於公布變更起十四天或更長時間後方始生效。不過,針對本服務新功能的變更,或基於法律理由而為之變更,將立即生效。如果您不同意本服務之修訂條款,則請停止使用該本服務。

第三人網站的連結 本服務或協力廠商可能會提供連結至其他網站或網路資源的連結。您可能會因此連結至其他業者經營的網站,但不表示希平方與該等業者有任何關係。其他業者經營的網站均由各該業者自行負責,不屬希平方控制及負責範圍之內。

兒童及青少年之保護 兒童及青少年上網已經成為無可避免之趨勢,使用網際網路獲取知識更可以培養子女的成熟度與競爭能力。然而網路上的確存有不適宜兒童及青少年接受的訊息,例如色情與暴力的訊息,兒童及青少年有可能因此受到心靈與肉體上的傷害。因此,為確保兒童及青少年使用網路的安全,並避免隱私權受到侵犯,家長(或監護人)應先檢閱各該網站是否有保護個人資料的「隱私權政策」,再決定是否同意提出相關的個人資料;並應持續叮嚀兒童及青少年不可洩漏自己或家人的任何資料(包括姓名、地址、電話、電子郵件信箱、照片、信用卡號等)給任何人。

為了維護 希平方 網站安全,我們需要您的協助:

您承諾絕不為任何非法目的或以任何非法方式使用本服務,並承諾遵守中華民國相關法規及一切使用網際網路之國際慣例。您若係中華民國以外之使用者,並同意遵守所屬國家或地域之法令。您同意並保證不得利用本服務從事侵害他人權益或違法之行為,包括但不限於:
A. 侵害他人名譽、隱私權、營業秘密、商標權、著作權、專利權、其他智慧財產權及其他權利;
B. 違反依法律或契約所應負之保密義務;
C. 冒用他人名義使用本服務;
D. 上載、張貼、傳輸或散佈任何含有電腦病毒或任何對電腦軟、硬體產生中斷、破壞或限制功能之程式碼之資料;
E. 干擾或中斷本服務或伺服器或連結本服務之網路,或不遵守連結至本服務之相關需求、程序、政策或規則等,包括但不限於:使用任何設備、軟體或刻意規避看 希平方 - 看 YouTube 學英文 之排除自動搜尋之標頭 (robot exclusion headers);

服務中斷或暫停
本公司將以合理之方式及技術,維護會員服務之正常運作,但有時仍會有無法預期的因素導致服務中斷或故障等現象,可能將造成您使用上的不便、資料喪失、錯誤、遭人篡改或其他經濟上損失等情形。建議您於使用本服務時宜自行採取防護措施。 希平方 對於您因使用(或無法使用)本服務而造成的損害,除故意或重大過失外,不負任何賠償責任。

版權宣告
上次更新日期:2013-09-16

希平方 內所有資料之著作權、所有權與智慧財產權,包括翻譯內容、程式與軟體均為 希平方 所有,須經希平方同意合法才得以使用。
希平方歡迎你分享網站連結、單字、片語、佳句,使用時須標明出處,並遵守下列原則:

  • 禁止用於獲取個人或團體利益,或從事未經 希平方 事前授權的商業行為
  • 禁止用於政黨或政治宣傳,或暗示有支持某位候選人
  • 禁止用於非希平方認可的產品或政策建議
  • 禁止公佈或傳送任何誹謗、侮辱、具威脅性、攻擊性、不雅、猥褻、不實、色情、暴力、違反公共秩序或善良風俗或其他不法之文字、圖片或任何形式的檔案
  • 禁止侵害或毀損希平方或他人名譽、隱私權、營業秘密、商標權、著作權、專利權、其他智慧財產權及其他權利、違反法律或契約所應付支保密義務
  • 嚴禁謊稱希平方辦公室、職員、代理人或發言人的言論背書,或作為募款的用途

網站連結
歡迎您分享 希平方 網站連結,與您的朋友一起學習英文。

抱歉傳送失敗!

不明原因問題造成傳送失敗,請儘速與我們聯繫!

「Rebecca Brachman:一種能預防憂鬱和創傷後壓力症候群的藥物」- Could a Drug Prevent Depression and PTSD?


框選或點兩下字幕可以直接查字典喔!

This is a tuberculosis ward, and at the time this picture was taken in the late 1800s, one in seven of all people died from tuberculosis. We had no idea what was causing this disease. The hypothesis was actually it was your constitution that made you susceptible. And it was a highly romanticized disease. It was also called consumption, and it was the disorder of poets and artists and intellectuals. And some people actually thought it gave you heightened sensitivity and conferred creative genius.

By the 1950s, we instead knew that tuberculosis was caused by a highly contagious bacterial infection, which is slightly less romantic, but that had the upside of us being able to maybe develop drugs to treat it. So doctors had discovered a new drug, iproniazid, that they were optimistic might cure tuberculosis, and they gave it to patients, and patients were elated. They were more social, more energetic. One medical report actually says they were "dancing in the halls." And unfortunately, this was not necessarily because they were getting better. A lot of them were still dying. Another medical report describes them as being "inappropriately happy." And that is how the first antidepressant was discovered.

So accidental discovery is not uncommon in science, but it requires more than just a happy accident. You have to be able to recognize it for discovery to occur.

As a neuroscientist, I'm going to talk to you a little bit about my firsthand experience with whatever you want to call the opposite of dumb luck—let's call it smart luck. But first, a bit more background.

Thankfully, since the 1950s, we've developed some other drugs and we can actually now cure tuberculosis. And at least in the United States, though not necessarily in other countries, we have closed our sanitoriums and probably most of you are not too worried about TB. But a lot of what was true in the early 1900s about infectious disease, we can say now about psychiatric disorders.

We are in the middle of an epidemic of mood disorders like depression and post-traumatic stress disorder, or PTSD. One in four of all adults in the United States suffers from mental illness, which means that if you haven't experienced it personally or someone in your family hasn't, it's still very likely that someone you know has, though they may not talk about it. Depression has actually now surpassed HIV/AIDS, malaria, diabetes and war as the leading cause of disability worldwide. And also, like tuberculosis in the 1950s, we don't know what causes it. Once it's developed, it's chronic, lasts a lifetime, and there are no known cures.

The second antidepressant we discovered, also by accident, in the 1950s, from an antihistamine that was making people manic, imipramine. And in both the case of the tuberculosis ward and the antihistamine, someone had to be able to recognize that a drug that was designed to do one thing—treat tuberculosis or suppress allergies—could be used to do something very different—treat depression. And this sort of repurposing is actually quite challenging. When doctors first saw this mood-enhancing effect of iproniazid, they didn't really recognize what they saw. They were so used to thinking about it from the framework of being a tuberculosis drug that they actually just listed it as a side effect, an adverse side effect.

As you can see here, a lot of these patients in 1954 are experiencing severe euphoria. And they were worried that this might somehow interfere with their recovering from tuberculosis. So they recommended that iproniazid only be used in cases of extreme TB and in patients that were highly emotionally stable, which is of course the exact opposite of how we use it as an antidepressant. They were so used to looking at it from the perspective of this one disease, they could not see the larger implications for another disease.

And to be fair, it's not entirely their fault. Functional fixedness is a bias that affects all of us. It's a tendency to only be able to think of an object in terms of its traditional use or function. And mental set is another thing. Right? That's sort of this preconceived framework with which we approach problems. And that actually makes repurposing pretty hard for all of us, which is, I guess, why they gave a TV show to the guy who was, like, really great at repurposing.

So the effects in both the case of iproniazid and imipramine, they were so strong—there was mania, or people dancing in the halls. It's actually not that surprising they were caught. But it does make you wonder what else we've missed. So iproniazid and imipramine, they're more than just a case study in repurposing. They have two other things in common that are really important. One, they have terrible side effects. That includes liver toxicity, weight gain of over 50 pounds, suicidality. And two, they both increase levels of serotonin, which is a chemical signal in the brain, or a neurotransmitter. And those two things together, right, one or the two, may not have been that important, but the two together meant that we had to develop safer drugs, and that serotonin seemed like a pretty good place to start.

So we developed drugs to more specifically focus on serotonin, the selective serotonin reuptake inhibitors, so the SSRIs, the most famous of which is Prozac. And that was 30 years ago, and since then we have mostly just worked on optimizing those drugs. And the SSRIs, they are better than the drugs that came before them, but they still have a lot of side effects, including weight gain, insomnia, suicidality—and they take a really long time to work, something like four to six weeks in a lot of patients. And that's in the patients where they do work. There are a lot of patients where these drugs don't work.

And that means now, in 2016, we still have no cures for any mood disorders, just drugs that suppress symptoms, which is kind of the difference between taking a painkiller for an infection versus an antibiotic. A painkiller will make you feel better, but is not going to do anything to treat that underlying disease. And it was this flexibility in our thinking that let us recognize that iproniazid and imipramine could be repurposed in this way, which led us to the serotonin hypothesis, which we then, ironically, fixated on. This is brain signaling, serotonin, from an SSRI commercial. In case you're not clear, this is a dramatization. And in science, we try and remove our bias, right, by running double-blinded experiments or being statistically agnostic as to what our results will be. But bias creeps in more insidiously in what we choose to study and how we choose to study it.

So we've focused on serotonin now for the past 30 years, often to the exclusion of other things. We still have no cures, and what if serotonin isn't all there is to depression? What if it's not even the key part of it? That means no matter how much time or money or effort we put into it, it will never lead to a cure.

In the past few years, doctors have discovered probably what is the first truly new antidepressant since the SSRIs, Calypsol, and this drug works very quickly, within a few hours or a day, and it doesn't work on serotonin. It works on glutamate, which is another neurotransmitter. And it's also repurposed. It was traditionally used as anesthesia in surgery. But unlike those other drugs, which were recognized pretty quickly, it took us 20 years to realize that Calypsol was an antidepressant, despite the fact that it's actually a better antidepressant, probably, than those other drugs. It's actually probably because of the fact that it's a better antidepressant that it was harder for us to recognize. There was no mania to signal its effects.

So in 2013, up at Columbia University, I was working with my colleague, Dr. Christine Ann Denny, and we were studying Calypsol as an antidepressant in mice. And Calypsol has, like, a really short half-life, which means it's out of your body within a few hours. And we were just piloting. So we would give an injection to mice, and then we'd wait a week, and then we'd run another experiment to save money.

And one of the experiments I was running, we would stress the mice, and we used that as a model of depression. And at first it kind of just looked like it didn't really work at all. So we could have stopped there. But I have run this model of depression for years, and the data just looked kind of weird. It didn't really look right to me. So I went back, and we reanalyzed it based on whether or not they had gotten that one injection of Calypsol a week beforehand. And it looked kind of like this. So if you look at the far left, if you put a mouse in a new space, this is the box, it's very exciting, a mouse will walk around and explore, and you can see that pink line is actually the measure of them walking. And we also give it another mouse in a pencil cup that it can decide to interact with. This is also a dramatization, in case that's not clear. And a normal mouse will explore. It will be social. Check out what's going on. If you stress a mouse in this depression model, which is the middle box, they aren't social, they don't explore. They mostly just kind of hide in that back corner, behind a cup. Yet the mice that had gotten that one injection of Calypsol, here on your right, they were exploring, they were social. They looked like they had never been stressed at all, which is impossible.

So we could have just stopped there, but Christine had also used Calypsol before as anesthesia, and a few years ago she had seen that it seemed to have some weird effects on cells and some other behavior that also seemed to last long after the drug, maybe a few weeks. So we were like, OK, maybe this is not completely impossible, but we were really skeptical.

So we did what you do in science when you're not sure, and we ran it again. And I remember being in the animal room, moving mice from box to box to test them, and Christine was actually sitting on the floor with the computer in her lap so the mice couldn't see her, and she was analyzing the data in real time. And I remember us yelling, which you're not supposed to do in an animal room where you're testing, because it had worked. It seemed like these mice were protected against stress, or they were inappropriately happy, however you want to call it. And we were really excited.

And then we were really skeptical, because it was too good to be true. So we ran it again. And then we ran it again in a PTSD model, and we ran it again in a physiological model, where all we did was give stress hormones. And we had our undergrads run it. And then we had our collaborators halfway across the world in France run it. And every time someone ran it, they confirmed the same thing. It seemed like this one injection of Calypsol was somehow protecting against stress for weeks.

And we only published this a year ago, but since then other labs have independently confirmed this effect. So we don't know what causes depression, but we do know that stress is the initial trigger in 80 percent of cases, and depression and PTSD are different diseases, but this is something they share in common. Right? It is traumatic stress like active combat or natural disasters or community violence or sexual assault that causes post-traumatic stress disorder, and not everyone that is exposed to stress develops a mood disorder. And this ability to experience stress and be resilient and bounce back and not develop depression or PTSD is known as stress resilience, and it varies between people. And we have always thought of it as just sort of this passive property. It's the absence of susceptibility factors and risk factors for these disorders. But what if it were active? Maybe we could enhance it, sort of akin to putting on armor.

We had accidentally discovered the first resilience-enhancing drug. And like I said, we only gave a tiny amount of the drug, and it lasted for weeks, and that's not like anything you see with antidepressants.

But it is actually kind of similar to what you see in immune vaccines. So in immune vaccines, you'll get your shots, and then weeks, months, years later, when you're actually exposed to bacteria, it's not the vaccine in your body that protects you. It's your own immune system that's developed resistance and resilience to this bacteria that fights it off, and you actually never get the infection, which is very different from, say, our treatments. Right? In that case, you get the infection, you're exposed to the bacteria, you're sick, and then you take, say, an antibiotic which cures it, and those drugs are actually working to kill the bacteria. Or similar to as I said before, with this palliative, you'll take something that will suppress the symptoms, but it won't treat the underlying infection, and you'll only feel better during the time in which you're taking it, which is why you have to keep taking it. And in depression and PTSD—here we have your stress exposure—we only have palliative care. Antidepressants only suppress symptoms, and that is why you basically have to keep taking them for the life of the disease, which is often the length of your own life.

So we're calling our resilience-enhancing drugs "paravaccines," which means vaccine-like, because it seems like they might have the potential to protect against stress and prevent mice from developing depression and post-traumatic stress disorder. Also, not all antidepressants are also paravaccines. We tried Prozac as well, and that had no effect.

So if this were to translate into humans, we might be able to protect people who are predictably at risk against stress-induced disorders like depression and PTSD. So that's first responders and firefighters, refugees, prisoners and prison guards, soldiers, you name it.

And to give you a sense of the scale of these diseases, in 2010, the global burden of disease was estimated at 2.5 trillion dollars, and since they are chronic, that cost is compounding and is therefore expected to rise up to six trillion dollars in just the next 15 years.

As I mentioned before, repurposing can be challenging because of our prior biases. Calypsol has another name, ketamine, which also goes by another name, Special K, which is a club drug and drug of abuse. It's still used across the world as an anesthetic. It's used in children. We use it on the battlefield. It's actually the drug of choice in a lot of developing nations, because it doesn't affect breathing. It is on the World Health Organization list of most essential medicines.

If we had discovered ketamine as a paravaccine first, it'd be pretty easy for us to develop it, but as is, we have to compete with our functional fixedness and mental set that kind of interfere. Fortunately, it's not the only compound we have discovered that has these prophylactic, paravaccine qualities, but all of the other drugs we've discovered, or compounds if you will, they're totally new, they have to go through the entire FDA approval process—if they make it before they can ever be used in humans. And that will be years. So if we wanted something sooner, ketamine is already FDA-approved. It's generic, it's available. We could develop it for a fraction of the price and a fraction of the time.

But actually, beyond functional fixedness and mental set, there's a real other challenge to repurposing drugs, which is policy. There are no incentives in place once a drug is generic and off patent and no longer exclusive to encourage pharma companies to develop them, because they don't make money. And that's not true for just ketamine. That is true for all drugs. Regardless, the idea itself is completely novel in psychiatry, to use drugs to prevent mental illness as opposed to just treat it.

It is possible that 20, 50, 100 years from now, we will look back now at depression and PTSD the way we look back at tuberculosis sanitoriums as a thing of the past. This could be the beginning of the end of the mental health epidemic.

But as a great scientist once said, "Only a fool is sure of anything. A wise man keeps on guessing."

Thank you, guys.

播放本句

登入使用學習功能

使用Email登入

HOPE English 播放器使用小提示

  • 功能簡介

    單句重覆、上一句、下一句:顧名思義,以句子為單位重覆播放,單句重覆鍵顯示橘色時為重覆播放狀態;顯示灰色時為正常播放狀態。按上一句鍵、下一句鍵時就會自動重覆播放該句。
    收錄佳句:點擊可增減想收藏的句子。

    中、英文字幕開關:中、英文字幕按鍵為綠色為開啟,灰色為關閉。鼓勵大家搞懂每一句的內容以後,關上字幕聽聽看,會發現自己好像在聽中文說故事一樣,會很有成就感喔!
    收錄單字:用滑鼠框選英文單字可以收藏不會的單字。
  • 分享
    如果您覺得本篇短片很有趣或很喜歡,在短片結束時有分享連結,可以分享給朋友一同欣賞,一起看YouTube學英文!

    或是您有收錄很優秀的句子時,也可以分享佳句給大家,一同看佳句學英文!